Back to top
more

Shockwave Medical Inc. (SWAV)

(Delayed Data from NSDQ)

$43.43 USD

43.43
437,633

+2.29 (5.57%)

Updated May 3, 2019 04:00 PM ET

After-Market: $43.32 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Investors Should Retain Integra (IART) Stock for Now

by Zacks Equity Research

Investors are optimistic about Integra's (IART) better-than-expected results and the continued demand for its products.

Tandem Diabetes (TNDM) Faces Expense Woes, Macro Issues

by Zacks Equity Research

Factoring in the pandemic and competitive pressure as well as evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) slashes full-year guidance.

Shaun Pruitt headshot

3 Top Ranked Stocks for Exposure to the Medical Sector

by Shaun Pruitt

The healthcare business offers attractive defensive attributes that are so valuable in the current uncertain environment. As such, adding healthcare stocks to the portfolio brings much needed diversification.

LHC Group's (LHCG) Latest Tie-Up to Improve Patient Services

by Zacks Equity Research

LHC Group's (LHCG) latest JV is expected to expand the availability of vital healthcare services to patients in the comfort of their homes.

Here's Why Investors Should Retain Globus Medical (GMED) For Now

by Zacks Equity Research

Investors are optimistic about Globus Medical's (GMED) better-than-expected results and new product introductions.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.

CVS Health (CVS) Progresses With Safe Medication Approach

by Zacks Equity Research

A major feature of CVS Health's (CVS) time delay safe function is that it cannot be overridden and is designed to deter pharmacy robbers.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Phirbo (PAHC) Faces Rising Costs and Inflationary Pressure

by Zacks Equity Research

Price competition coming from cheap generic alternatives of a few Phirbo (PAHC) products is a deterrent.

QIAGEN (QGEN) to Develop Companion Diagnostic for Neuron23

by Zacks Equity Research

QIAGEN's (QGEN) novel companion diagnostic assay will help identify individuals who might benefit from Neuron23's drug candidate for Parkinson's disease.

BD's (BDX) Latest PFS Launch to Boost Production Efficiencies

by Zacks Equity Research

BD's (BDX) newest product offering is expected to set a new standard in performance for vaccine PFS with new and strict specifications for improved production efficiencies.

Haemonetics (HAE) to Offer Two VASCADE Devices in the EU

by Zacks Equity Research

Haemonetics' (HAE) VASCADE and VASCADE MVP devices help patients attain hemostasis more quickly and with lesser complications.

Cardinal Health (CAH) Lowers Medical Segment Income Guidance

by Zacks Equity Research

Cardinal Health (CAH) projects Medical segment loss to be in the range of $25 million to $55 million for the first quarter of fiscal 2023, owing to inventory charges related to the company's gloves portfolio.

3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Merit Medical's (MMSI) Latest Launch to Boost Patient Care

by Zacks Equity Research

Merit Medical's (MMSI) latest addition to its portfolio is expected to ease access to difficult anatomy in the peripheral vasculature, thereby serving a wider patient pool.

AmerisourceBergen (ABC) to Buy Germany's PharmaLex for $1.3B

by Zacks Equity Research

AmerisourceBergen (ABC) inks a deal to acquire PharmaLex to support its goal to become a strategic partner of choice for pharma customers for clinical and commercial enablement solutions.

Alcon (ALC) Faces Cost Pressure, Supply Chain Disruption

by Zacks Equity Research

Given the supply chain challenges, unfavorable foreign exchange impact and inflationary pressure, Alcon (ALC) reduces its core EPS and net sales expectations for 2022.

Here's Why Investors Should Retain Syneos Health (SYNH) for Now

by Zacks Equity Research

Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental results.

Edwards Lifesciences (EW) Debuts SAPIEN 3 Ultra RESILIA Valve

by Zacks Equity Research

Edwards Lifesciences' (EW) SAPIEN 3 Ultra RESILIA valve combines its breakthrough RESILIA tissue technology with the SAPIEN 3 Ultra transcatheter aortic heart valve.

Why Should You Add Ensign Group (ENSG) to Portfolio Now?

by Zacks Equity Research

Ensign Group (ENSG) benefits from a growing healthcare portfolio as a result of multiple facility buyouts. Solid cash-generating abilities empower ENSG to invest in growth-related initiatives.

Here's Why You Should Hold on to Ecolab (ECL) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.

Globus Medical (GMED) Gains Market Share, Cost Woes Stay

by Zacks Equity Research

Globus Medical (GMED) U.S. sales increase, driven by competitive rep conversions and robotic pull-through.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Charles River (CRL) to Support Cure AP-4's Clinical Trials

by Zacks Equity Research

Charles River's (CRL) manufacturing collaboration with Cure AP-4 will support the latter's Phase I/II gene therapy trials for a rare neurodegenerative disorder.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.